A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Principal Investigator
-
Sponsor
Loxo Oncology, Inc.
You are being invited to take part in this study because you have been diagnosed with a type of cancer that may express a protein called nectin-4, which LY4101174 is designed to treat and you have already received standard therapies for your disease that your cancer either did not respond to, or your cancer progressed, or you did not tolerate this treatment, or your doctor does not think standard treatment will be effective or tolerated.
Enrollment Form
This study is currently enrolling.